EUVIMEDEUVIMED entdecken
Kommentar

Patent Listing Challenges by the Federal Trade Commission

Anna Hung, Cary P Gross

JAMA Internal Medicine · 01.07.2026 · 186 (7) · 801

DOI: 10.1001/jamainternmed.2026.0987 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2026. Verfasst von Anna Hung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Editorial Fellow, JAMA Internal Medicine. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Editorial Fellow, JAMA Internal Medicine.
  • Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
  • Duke-Margolis Institute for Health Policy, Durham, North Carolina.
  • Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, Durham, North Carolina.
  • Associate Editor, JAMA Internal Medicine.
  • National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut.

Zitieren

APA

Hung, A., & Gross, C. P. (2026). Patent Listing Challenges by the Federal Trade Commission. JAMA Internal Medicine, 186(7), 801. https://doi.org/10.1001/jamainternmed.2026.0987

Vancouver

Hung A, Gross CP. Patent Listing Challenges by the Federal Trade Commission. JAMA Internal Medicine. 2026;186(7):801. doi:10.1001/jamainternmed.2026.0987

BibTeX
@article{Hung2026,
  author = {Hung, Anna and Gross, Cary P},
  title = {Patent Listing Challenges by the Federal Trade Commission},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {7},
  pages = {801},
  doi = {10.1001/jamainternmed.2026.0987}
}
Kostenlos starten →